Korsana Biosciences, Inc. Common Stock
KRSA
21 hedge funds and large institutions have $11.2M invested in Korsana Biosciences, Inc. Common Stock in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
7,169% more capital inflows, than outflows
Capital inflows: $10.3M | Capital outflows: $142K
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
72.05% more ownership
Funds ownership: 4.13% → 76.17% (+72%)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
31% more funds holding
Funds holding: 16 → 21 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kalehua Capital Management
Dallas,
Texas
|
+$5.36M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.09M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.03M |
| 4 |
ADAR1 Capital Management
Austin,
Texas
|
+$969K |
| 5 |
Braidwell
Stamford,
Connecticut
|
+$509K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$126K |
| 2 |
Kovack Advisors
Ft. Lauderdale,
Florida
|
-$15.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$818 |
| 4 |
MAI Capital Management
Independence,
Ohio
|
-$155 |
| 5 |
Citigroup
New York
|
-$137 |
KRSA Hedge Fund Activity: Q2 2026 in Review
21 of the 8,372 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q2 2026, worth a combined $11.2M — up 4,390% from $249K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new KRSA positions and 4 closed out — a net gain of 5 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Kalehua Capital Management, opening a new position worth an estimated $5.36M. The largest seller was Geode Capital Management, cutting an estimated $126K.
- 21 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q2 2026, up from 16 in Q1 2026.
- Funds reported $11.2M of Korsana Biosciences, Inc. Common Stock stock for Q2 2026, up 4,390% quarter-over-quarter.
- 9 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q2 2026 and 4 closed out, a net change of +5 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q2 2026 was Kalehua Capital Management, an estimated $5.36M added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q2 2026 was Geode Capital Management, an estimated $126K sold.
Based on aggregated 13F filings for Q2 2026.